{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:36:34Z","timestamp":1789616194150,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ecl.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T23:35:46Z","timestamp":1749512146000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Update in Papillary Thyroid Cancer"],"prefix":"10.1016","volume":"54","author":[{"given":"William","family":"Kuenstner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Alzedaneen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/thy.2018.0462","article-title":"Active surveillance for T1bN0M0 papillary thyroid carcinoma","volume":"29","author":"Sakai","year":"2019","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.007_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4158\/EP.13.5.521","article-title":"Management of patients with low-risk papillary thyroid carcinoma","volume":"13","author":"Hay","year":"2007","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.007_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4158\/EP.13.5.498","article-title":"Management of low-risk differentiated thyroid cancer","volume":"13","author":"Mazzaferri","year":"2007","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/thy.2013.0367","article-title":"Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation","volume":"24","author":"Ito","year":"2014","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.007_bib5","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1007\/s00268-009-0359-x","article-title":"Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes","volume":"34","author":"Sugitani","year":"2010","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for Adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.007_bib7","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1210\/clinem\/dgz113","article-title":"Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center","volume":"105","author":"Molinaro","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.007_bib8","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/thy.2018.0263","article-title":"Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea","volume":"28","author":"Oh","year":"2018","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.007_bib9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamaoto.2018.1663","article-title":"Active surveillance in thyroid microcarcinoma in a Latin-American cohort","volume":"144","author":"Sanabria","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.007_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1089\/thy.2018.0609","article-title":"Tumor volume doubling time in active surveillance of papillary thyroid carcinoma","volume":"29","author":"Oh","year":"2019","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.007_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00268-015-3349-1","article-title":"Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance","volume":"40","author":"Fukuoka","year":"2016","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101630","article-title":"Active surveillance of low-risk papillary thyroid microcarcinoma","volume":"37","author":"Sugitani","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/lio2.356","article-title":"Active surveillance for patients with very low-risk thyroid cancer","volume":"5","author":"Lohia","year":"2020","journal-title":"Laryngoscope Investig Oto"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/thy.2015.0178","article-title":"A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.007_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/SLA.0b013e31814697d9","article-title":"Extent of surgery affects survival for papillary thyroid cancer","volume":"246","author":"Bilimoria","year":"2007","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.007_bib16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/archoto.2010.181","article-title":"Surgery for papillary thyroid carcinoma: is lobectomy enough?","volume":"136","author":"Mendelsohn","year":"2010","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.007_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hed.21504","article-title":"Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer","volume":"33","author":"Barney","year":"2011","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.007_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/SLA.0000000000000925","article-title":"Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients","volume":"260","author":"Adam","year":"2014","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10434-004-1165-1","article-title":"Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer","volume":"12","author":"Haigh","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00268-013-2224-1","article-title":"Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases","volume":"38","author":"Matsuzu","year":"2014","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.007_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.surg.2011.08.016","article-title":"Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy","volume":"151","author":"Nixon","year":"2012","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.007_bib22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.21037\/gs-20-712","article-title":"Thyroid lobectomy in patients with differentiated thyroid cancer: an analysis of the clinical outcomes in a nationwide multicenter study","volume":"10","author":"D\u00edez","year":"2021","journal-title":"Gland Surg"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.007_bib23","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.3390\/cancers12113282","article-title":"Thyroid lobectomy for low to intermediate risk differentiated thyroid cancer","volume":"12","author":"Hartl","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.007_bib24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000510620","article-title":"Long-term outcome of lobectomy for thyroid cancer","volume":"10","author":"Bosset","year":"2021","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ecl.2025.03.007_bib25","author":"Haddad"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000345498","article-title":"Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications","volume":"75","author":"Kandil","year":"2013","journal-title":"ORL"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.007_bib27","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1245\/s10434-014-3846-8","article-title":"Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons","volume":"21","author":"Hauch","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.007_bib28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/SLA.0000000000001688","article-title":"Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes?","volume":"265","author":"Adam","year":"2017","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.surg.2016.05.056","article-title":"Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine","volume":"161","author":"Kluijfhout","year":"2017","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.007_bib30","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/jc.2015-4290","article-title":"Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine","volume":"101","author":"Momesso","year":"2016","journal-title":"J Clin Endocrinol Metabol"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.007_bib31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1089\/thy.2018.0046","article-title":"Changes in serum thyroglobulin levels after lobectomy in patients with low-risk papillary thyroid cancer","volume":"28","author":"Park","year":"2018","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.007_bib32","doi-asserted-by":"crossref","first-page":"e2145","DOI":"10.1210\/clinem\/dgaa152","article-title":"Detecting recurrence following lobectomy for thyroid cancer: role of thyroglobulin and thyroglobulin antibodies","volume":"105","author":"Ritter","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.007_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2265.2011.04002.x","article-title":"Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer","volume":"75","author":"Vaisman","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.007_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejso.2017.07.004","article-title":"Post-treatment surveillance of thyroid cancer","volume":"44","author":"Wang","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.007_bib35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0039-6060(05)80124-2","article-title":"Prognostic factors and risk group analysis in follicular carcinoma of the thyroid","volume":"118","author":"Shaha","year":"1995","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.007_bib36","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/thy.2018.0775","article-title":"Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation","volume":"30","author":"Zahedi","year":"2020","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.007_bib37","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1089\/thy.2015.0104","article-title":"Survival from differentiated thyroid cancer: what has age got to do with it?","volume":"25","author":"Ganly","year":"2015","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.007_bib38","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1210\/jc.2005-0671","article-title":"Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas","volume":"90","author":"Spencer","year":"2005","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.007_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2265.2002.01592.x","article-title":"Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation","volume":"57","author":"Chung","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.007_bib40","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1210\/jc.2008-0962","article-title":"Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma","volume":"93","author":"Kim","year":"2008","journal-title":"J Clin Endocrinol Metabol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.007_bib41","first-page":"592","article-title":"Can risk-adapted treatment recommendations replace the \u201cone size fits all\u201d approach for early-stage thyroid cancer patients?","volume":"23","author":"Tuttle","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.007_bib42","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"issue":"23","key":"10.1016\/j.ecl.2025.03.007_bib43","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1002\/cncr.29633","article-title":"Cost-effectiveness analysis of papillary thyroid cancer surveillance","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.007_bib44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/thy.1998.8.737","article-title":"Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the national thyroid cancer treatment cooperative Registry","volume":"8","author":"Cooper","year":"1998","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.007_bib45","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.007_bib46","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1210\/JC.2015-1346","article-title":"Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS Registry analysis 1987\u20132012","volume":"100","author":"Carhill","year":"2015","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.007_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7754","article-title":"Association of thyrotropin suppression with survival outcomes in patients with intermediate- and high-risk differentiated thyroid cancer","volume":"2","author":"Klubo-Gwiezdzinska","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.007_bib48","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1210\/jc.2010-0161","article-title":"Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial","volume":"95","author":"Sugitani","year":"2010","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.007_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1515\/fco-2015-0010","article-title":"The efficacy of thyrotropin suppression therapy in treatment of differentiated thyroid cancer after total thyroidectomy","volume":"6","author":"Abo-Touk","year":"2015","journal-title":"Forum Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.007_bib50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1089\/thy.2023.0711","article-title":"The effect of thyrotropin suppression on survival outcomes in patients with differentiated thyroid cancer: a systematic review and meta-analysis","volume":"34","author":"Gubbi","year":"2024","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.ecl.2025.03.007_bib51","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab576","article-title":"Cardiovascular outcomes in thyroid cancer patients treated with thyroidectomy: a meta-analysis","author":"Lee","year":"2021","journal-title":"J Clin Endocrinol Metabol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:02:45Z","timestamp":1753484565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0889852925000295"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.007","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update in Papillary Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}